AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Ionis Pharmaceuticals Inc... (IONS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

32.08

1.04 (3.35%)

At close: Feb 18, 2025, 3:59 PM

33.50

4.43%

After-hours: Feb 18, 2025, 06:20 PM EST

undefined% (undefined)

Bid	32.1
Market Cap	5.07B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.44
PE Ratio (ttm)	-13.15
Forward PE	n/a
Analyst	Buy

Ask	34
Volume	1,691,256
Avg. Volume (20D)	1,569,581
Open	31.34
Previous Close	31.04
Day's Range	31.11 - 32.09
52-Week Range	30.23 - 52.34
Beta	undefined

About IONS

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 17, 1991

Employees 927

Stock Exchange NASDAQ

Ticker Symbol IONS

Website https://www.ionispharma.com

Full Company Profile

Analyst Forecast

According to 17 analyst ratings, the average rating for IONS stock is "Buy." The 12-month stock price forecast is $62, which is an increase of 93.27% from the latest price.

Buy 64.71%

Hold 29.41%

Sell 5.88%

Stock Forecasts

Next Earnings Release

Ionis Pharmaceuticals Inc. is scheduled to release its earnings on Feb 19, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-7.76%

Shares of pharmaceutical and healthcare stocks are... Unlock content with Pro Subscription

5 months ago

-12.29%

Ionis Pharmaceuticals shares are trading lower after the company priced its $500.3 million public offering of 11.5 million common shares at $43.50 per share.

News

1 day ago · zacks.com

Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS

Evaluate the expected performance of Ionis Pharmaceuticals (IONS) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of i...

6 days ago · zacks.com

Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Should You Buy?

Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · businesswire.com

Ionis to hold fourth quarter and full year 2024 financial results webcast

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19th at 11:30 a.m. Eastern Time to discuss its fou...

1 month ago · seekingalpha.com

Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval

Ionis Pharmaceuticals applies proprietary antisense technology to tackle diseases at their genetic source, focusing on conditions such as FCS, Angelman syndrome, and HAE. The FDA approval of Tryngolza...

2 months ago · zacks.com

Ionis Gets FDA Approval for Rare Disease Drug Tryngolza

The FDA's nod to IONS' Tryngolza makes it the first approved treatment for FCS. It is also the company's first wholly-owned drug to receive marketing approval.

2 months ago · benzinga.com

FDA Approves Ionis Pharmaceuticals' Rare Genetic Disease Therapy to Lower High-Level Of Fat In Blood

On Thursday, the FDA approved Ionis Pharmaceuticals, Inc.'s IONS Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), a rare, gen...

2 months ago · reuters.com

US FDA approves Ionis Pharma's genetic disorder drug

The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's website showed ...

2 months ago · zacks.com

How Much Upside is Left in Ionis Pharmaceuticals (IONS)? Wall Street Analysts Think 55.91%

The mean of analysts' price targets for Ionis Pharmaceuticals (IONS) points to a 55.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

2 months ago · zacks.com

Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?

Ionis Pharmaceuticals (IONS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).